Cerus Q4 revenue $50.1M (+49% YoY); reiterates FY2022 product revenue guidance $157-164M

CERUS CORP

2022-FY EPS reported -$0.32 revenue$159,518,000

Q4 product revenue $39.9M (+41% YoY); net loss narrowed to $9.1M ($0.05/sh) from $14.4M.
FY2021 total revenue $159.5M (+40% YoY); product revenue $130.9M (+42% YoY).
FY2022 product revenue guidance reaffirmed at $157-164M, representing 20-25% growth.
Two blood centers obtained BLA approvals for INTERCEPT Fibrinogen Complex (IFC), enabling interstate sales.
Cash, equivalents and short-term investments $129.4M at Dec 31, 2021; net cash used in ops $33.9M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.